Genxone (WAR:GX1) Debt-to-Revenue : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Genxone Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Genxone's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was zł0.00 Mil. Genxone's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was zł0.00 Mil. Genxone's annualized Revenue for the quarter that ended in Dec. 2024 was zł2.40 Mil. Genxone's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.

Genxone Debt-to-Revenue Historical Data

The historical data trend for Genxone's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genxone Debt-to-Revenue Chart

Genxone Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Revenue

Get a 7-Day Free Trial

Genxone Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Genxone's Debt-to-Revenue

For the Biotechnology subindustry, Genxone's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genxone's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genxone's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Genxone's Debt-to-Revenue falls into.

Save Embed

;

Save Embed

;

Genxone Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Genxone's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	1.788
	=	0.00

Genxone's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	2.404
	=	0.00

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.

Genxone Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Genxone's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Genxone Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genxone SA (WAR:GX1) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

ul. Kobaltowa 6, Zlotniki, Suchy Las, POL, 62-002

Website

https://www.genxone.eu

Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.

Genxone Headlines

No Headlines